K36 Therapeutics, Inc.

Founded in February 2021, K36 Therapeutics is a privately held biotechnology company backed by Atlas Venture, F-Prime, Eight Roads Ventures, Nextech and Bristol Myers Squibb. Our mission is to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics for the benefit of cancer patients worldwide. For more information, please visit www.k36tx.com.

 

Industries
Biotechnology
Pharmaceuticals
Life Sciences
Healthcare
Drug Development
Oncology
Immunotherapy
Precision Medicine
Cancer Research
Clinical Trials



Office Locations
1 Main Street, c/o F-Prime 13 floor, Cambridge, MA 02142
Contact Information
K36 Therapeutics
Soo Bang
[email protected]
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

Feb 24, 2026, 08:00 ET K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026

K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with high...

Feb 05, 2026, 10:59 ET K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO

K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet ...

Dec 05, 2025, 08:00 ET K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer

K36 Therapeutics, Inc. ("K36"), a clinical-stage biotechnology company developing first-in-class MMSET/NSD2 inhibitors for genetically defined...

Sep 18, 2025, 07:00 ET K36 Therapeutics to Present New Preclinical Data Supporting Ongoing Phase 1 Clinical Trial of KTX-1001 at the 22nd Annual International Myeloma Society Meeting

K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet...

Sep 16, 2025, 07:00 ET K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma

K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet...

Aug 07, 2025, 08:00 ET K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration with Bayer for Supply of Darolutamide

K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet...

Dec 03, 2024, 08:00 ET K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Meeting

K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET / NSD2 inhibitor KTX-1001 for t(4;14) ...

Dec 04, 2023, 08:00 ET K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14)...

Nov 15, 2023, 08:00 ET K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14)...

Jun 28, 2023, 08:00 ET K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

K36 Therapeutics ("K36"), a privately held clinical-stage biotech company developing KTX-1001, an investigational small molecule methyltransferase...

Apr 11, 2023, 08:00 ET K36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multiple myeloma and addition of Mr. Michael Heffernan as Independent Board Director

K36 Therapeutics ("K36"), a privately held biotechnology company developing KTX-1001, an investigational small molecule methyltransferase inhibitor...

Aug 23, 2022, 07:00 ET K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001

K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing novel targeted therapies for the unmet medical needs of cancer...

Dec 09, 2021, 07:00 ET K36 Therapeutics Launches with $30 Million Series A Financing from F-Prime Capital and Atlas Venture with Eight Roads Ventures

K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing breakthrough therapies for the unmet medical needs of cancer...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.